Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Fellowship - Priority Announcement - Diabetes

University of Toronto

$67,500.00

Investigation of GABAA-R PAM-stimulated beta-cell regeneration and its correction of hyperglycemia and glucose intolerance in prediabetes and type 2 diabetes

FY 2017-18

Summary
The development of medications to safely promote ß-cell replication would be ground-breaking for the treatment of all forms of diabetes. GABA, a neurotransmitter, was shown to facilitate ß-cell regeneration in mice. However, GABA exerts unspecific effects, mainly due to the activation of its various receptors, leading to cellular events unrelated to proliferation. Specific positive allosteric modulators (PAMs) of GABA offer increased specificity and are currently in clinical use. I hypothesize that GABAA-R PAM will increase ß-cell mass in both normal mice and those with experimental diabetes (prediabetes and type 2 diabetes [T2D]), being more effective than GABA itself. Repurposing GABAA-R PAMs to treat diabetes is theoretically appealing due to their safety profile and potential to enhance the ability of GABA to promote ß-cell replication. Part 1 of the study will focus on the PAM-mediated effect(s) on ß-cell proliferation. Pancreatic islet expansion and ß-cell regeneration will be evaluated in mice treated with GABAA-R PAMs. To explore the potential use of PAM drugs as an anti-diabetic tool, prediabetic and T2D mice models will be used; thereafter, ß-cell proliferation and islet mass will be assessed. I will also verify whether hyperglycemia and glucose intolerance was corrected with PAM administration. Part 2 will focus on the functional and mechanistic effect(s) of PAMs on ß-cell function and expansion. I will measure insulin release, insulin granules and the gene levels of proinsulin and preproinsulin in mice and human islets. The mechanism of PAM-mediated ß-cell expansion will also be rigorously assessed through a variety of ex vitro experiments. In the end, I will determine the PAMs' 1) effectiveness to expand ß-cell mass; 2) ability to correct hyperglycemia in prediabetes and T2D; and 3) functional and mechanistic effect(s) on mouse and human pancreatic ß-cells. This study could usher in a new class of drugs for diabetes treatment.
Program
Fellowship - Priority Announcement - Diabetes
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
379175
Name
Untereiner Ashley
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Diabetes Canada (Toronto, Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Investigation of GABAA-R PAM-stimulated beta-cell regeneration and its correction of hyperglycemia and glucose intolerance in prediabetes and type 2 diabetes
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Diabetes
Keyworddelim
Beta-Cell Proliferation; Gaba; Pre-Diabetes; Regenerative Medicine; Type 2 Diabetes
Abstract
The development of medications to safely promote ß-cell replication would be ground-breaking for the treatment of all forms of diabetes. GABA, a neurotransmitter, was shown to facilitate ß-cell regeneration in mice. However, GABA exerts unspecific effects, mainly due to the activation of its various receptors, leading to cellular events unrelated to proliferation. Specific positive allosteric modulators (PAMs) of GABA offer increased specificity and are currently in clinical use. I hypothesize that GABAA-R PAM will increase ß-cell mass in both normal mice and those with experimental diabetes (prediabetes and type 2 diabetes [T2D]), being more effective than GABA itself. Repurposing GABAA-R PAMs to treat diabetes is theoretically appealing due to their safety profile and potential to enhance the ability of GABA to promote ß-cell replication. Part 1 of the study will focus on the PAM-mediated effect(s) on ß-cell proliferation. Pancreatic islet expansion and ß-cell regeneration will be evaluated in mice treated with GABAA-R PAMs. To explore the potential use of PAM drugs as an anti-diabetic tool, prediabetic and T2D mice models will be used; thereafter, ß-cell proliferation and islet mass will be assessed. I will also verify whether hyperglycemia and glucose intolerance was corrected with PAM administration. Part 2 will focus on the functional and mechanistic effect(s) of PAMs on ß-cell function and expansion. I will measure insulin release, insulin granules and the gene levels of proinsulin and preproinsulin in mice and human islets. The mechanism of PAM-mediated ß-cell expansion will also be rigorously assessed through a variety of ex vitro experiments. In the end, I will determine the PAMs' 1) effectiveness to expand ß-cell mass; 2) ability to correct hyperglycemia in prediabetes and T2D; and 3) functional and mechanistic effect(s) on mouse and human pancreatic ß-cells. This study could usher in a new class of drugs for diabetes treatment.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Untereiner, Ashley
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $67,500~ $0~